Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
To qualify, a person must be enrolled in a Medicare Part D plan and meet one of three clinical criteriaassessed at the time you first started GLP-1 therapy, not at the time you apply: BMI of 35 or higher (no additional diagnosis required) BMI of 30 or higher, plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension on two or more blood pressure medications, or chronic kidney disease stage 3a or higher BMI of 27 or higher, plus a diagnosis of pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease Your provider submits a prior authorization request attesting you meet the criteriayou dont need to opt in or take any action yourself
These drugs are powerful tools, but not quick fixes
In trials to assess semaglutides effectiveness for reducing the risk of major cardiovascular events in adults, more people taking Wegovy developed kidney stones than those on placebo 1.2% vs 0.8% respectively
No lethal dose was reached in preclinical toxicology studies, and no significant adverse effects have been reported in published research
If a dose is missed, it should not be taken later on the same day, but should be skipped
